Related Experiment Video
Updated: Jul 10, 2026
12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Outcomes of Neoadjuvant Radiotherapy Followed by Robotic Radical Prostatectomy in High-Risk Locally Advanced Prostate
Chi-Shin Tseng1,2, Chih-Kai Chang3, Hsing-Ju Li4
1Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Annals of Surgical Oncology
|July 9, 2026
Summary
Neoadjuvant radiotherapy (RT) combined with androgen-deprivation therapy (ADT) before prostatectomy is feasible for high-risk prostate cancer. While it showed pathological downstaging, more research is needed to confirm oncologic benefits.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Neoadjuvant radiotherapy (RT) for prostate cancer is an emerging treatment strategy.
- High-risk locally advanced prostate cancer requires effective treatment protocols.
Purpose of the Study:
- To assess the feasibility and safety of neoadjuvant RT with androgen-deprivation therapy (ADT) followed by robot-assisted radical prostatectomy (RP).
- To evaluate preliminary oncological and functional outcomes in patients with high-risk locally advanced prostate cancer.
Main Methods:
- Prospective enrollment of patients with high-risk locally advanced prostate cancer.
- Administration of neoadjuvant RT (50 Gy in 25 fractions) with 3 months of ADT, followed by robot-assisted RP.
- Comparison with a retrospective cohort of patients who underwent RP alone.
Main Results:
- No major perioperative complications were observed in the neoadjuvant RT group.
- Pathological downstaging occurred in 60% of patients receiving neoadjuvant RT, compared to none in the control group.
- MRI-derived imaging biomarkers showed potential predictive value for pathological outcomes.
Conclusions:
- Neoadjuvant RT with ADT followed by RP is a feasible and well-tolerated treatment for high-risk locally advanced prostate cancer.
- Pathological downstaging was observed, but larger prospective studies are necessary to confirm oncologic benefits.